Literature DB >> 20849901

The state of antibody therapy.

Ali Elbakri1, Paul N Nelson, Raed O Abu Odeh.   

Abstract

Therapeutic antibodies are widely used in the treatment of various diseases and disease conditions, including cardiovascular diseases, autoimmune disorders, malignancies, and infections. With at least 23 therapeutic agents currently in clinical use and a successful business generating large revenues, major technological advances are now in place to improve the specificity and efficacy of those antibodies already in the market and also generate new, safe and effective macromolecules for the treatment of other ailments. This review provides a summary of the current state of antibody therapy, highlights and discusses recent developments in the field of antibody-based therapeutics production, combination therapy and shows the status of some of the agents that are in clinical trial.
Copyright © 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849901     DOI: 10.1016/j.humimm.2010.09.007

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  15 in total

1.  Protein G, protein A and protein A-derived peptides inhibit the agitation induced aggregation of IgG.

Authors:  Jun Zhang; Elizabeth M Topp
Journal:  Mol Pharm       Date:  2012-02-09       Impact factor: 4.939

2.  Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.

Authors:  Kobra Omidfar; Fatemeh Sadat Amjad Zanjani; Arghavan Golbaz Hagh; Maedeh Darziani Azizi; Seyed Javad Rasouli; Susan Kashanian
Journal:  Mol Biol Rep       Date:  2013-09-20       Impact factor: 2.316

Review 3.  Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

Authors:  Patrick J McEnaney; Christopher G Parker; Andrew X Zhang; David A Spiegel
Journal:  ACS Chem Biol       Date:  2012-07-03       Impact factor: 5.100

4.  Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.

Authors:  Srinath Kasturirangan; Tim Reasoner; Philip Schulz; Shanta Boddapati; Sharareh Emadi; Jon Valla; Michael R Sierks
Journal:  Biotechnol Prog       Date:  2013-03-07

5.  Research and development of therapeutic mAbs: An analysis based on pipeline projects.

Authors:  Xiaomei Geng; Xiangjun Kong; Hao Hu; Jiayu Chen; Fengqing Yang; Hongyu Liang; Xin Chen; Yuanjia Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Theory for the Liquid-Liquid Phase Separation in Aqueous Antibody Solutions.

Authors:  Miha Kastelic; Vojko Vlachy
Journal:  J Phys Chem B       Date:  2018-01-27       Impact factor: 2.991

7.  Identification of Eps15 as antigen recognized by the monoclonal antibodies aa2 and ab52 of the Wuerzburg Hybridoma Library against Drosophila brain.

Authors:  Partho Halder; Yi-Chun Chen; Janine Brauckhoff; Alois Hofbauer; Marie-Christine Dabauvalle; Urs Lewandrowski; Christiane Winkler; Albert Sickmann; Erich Buchner
Journal:  PLoS One       Date:  2011-12-19       Impact factor: 3.240

Review 8.  Nanobodies as novel agents for disease diagnosis and therapy.

Authors:  Christina G Siontorou
Journal:  Int J Nanomedicine       Date:  2013-01-11

9.  Assessment of the evolution of cancer treatment therapies.

Authors:  Manuel Arruebo; Nuria Vilaboa; Berta Sáez-Gutierrez; Julio Lambea; Alejandro Tres; Mónica Valladares; Africa González-Fernández
Journal:  Cancers (Basel)       Date:  2011-08-12       Impact factor: 6.639

10.  High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.

Authors:  Kristof Zarschler; Stefanie Witecy; Franz Kapplusch; Christian Foerster; Holger Stephan
Journal:  Microb Cell Fact       Date:  2013-10-27       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.